Company Description
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy.
The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's.
In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia.
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015.
ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Neil Warma |
Contact Details
Address: 1920 Yonge Street, Suite 200 Toronto, ON M4S 3E2 Canada | |
| Phone | 416 847 6898 |
| Website | promisneurosciences.com |
Stock Details
| Ticker Symbol | PMN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001374339 |
| CUSIP Number | 74346M406 |
| ISIN Number | CA74346M4065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Neil K. Warma M.B.A. | Chief Executive Officer, President, Compliance Officer and Director |
| Eugene W. Williams | Co-Founder and Chairman |
| Dr. Neil R. Cashman M.D. | Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer and Director |
| Daniel E. Geffken M.B.A. | Chief Financial Officer |
| Dr. Johanne Kaplan Ph.D. | Chief Development Officer |
| Dr. David Wishart Ph.D. | Chief Physics Officer |
| Dennis Chen Ph.D. | Head of Manufacturing and Senior Consultant |
| Dr. Larry Douglas Altstiel M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 3, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 3, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 30, 2025 | 8-K | Current Report |
| Sep 23, 2025 | PRE 14A | Other preliminary proxy statements |
| Sep 10, 2025 | EFFECT | Notice of Effectiveness |
| Sep 4, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 3, 2025 | 8-K | Current Report |
| Aug 22, 2025 | EFFECT | Notice of Effectiveness |
| Aug 20, 2025 | UPLOAD | Filing |
| Aug 19, 2025 | 8-K | Current Report |